The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Selecta Biosciences Inc. (SELB) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.03, or -2.63%, to $1.11. The Selecta Biosciences Inc. has recorded 12,289 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics.
Selecta Biosciences Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.14 and fluctuated between $1.1600 as its day high and $1.1201 as its day low. The current market capitalization of Selecta Biosciences Inc. is $174.90M. A total of 1.18 million shares were traded on the day, compared to an average of 963.22K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, SELB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 5 BUYs and 22 SELLs from insiders. Insiders purchased 693,738 shares during that period but sold 218,496.
In the most recent transaction, Brunn Carsten sold 13,473 shares of SELB for 1.13 per share on Jan 05. After the transaction, the President and CEO now owns 786,013 company shares. In a previous transaction on Jan 05, TRABER PETER G sold 3,465 shares at 1.13 per share. SELB shares that Chief Medical Officer owns now total 446,121.
Among the insiders who sold shares, Kishimoto Takashi Kei disposed of 3,392 shares on Jan 05 at a per-share price of $1.13. This resulted in the Chief Scientific Officer holding 364,316 shares of SELB after the transaction. In another insider transaction, Johnston Lloyd P. sold 3,392 shares at $1.13 per share on Jan 05. Company shares held by the Chief Operations Officer now total 265,515.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for SELB in the last 3 months, the mean price target is $3.50 with high estimates of $5.00 and low estimates of $1.00. In terms of 52-week highs and lows, SELB has a high of $1.99 and a low of $0.90.
As of this writing, SELB has an earnings estimate of -$0.06 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $0.04 per share and a lower estimate of -$0.1. The company reported an EPS of -$0.14 in the last quarter, which was -55.60% lower than expectations of -$0.09.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SELB’s latest balance sheet shows that the firm has $128.06M in Cash & Short Term Investments as of fiscal 2021. There were $35.28M in debt and $72.25M in liabilities at the time. Its Book Value Per Share was $0.43, while its Total Shareholder’s Equity was $22.52M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SELB is Buy with a score of 4.50.